Two months after completing its $20.1 billion buyout of Genzyme Corp., drug giant Sanofi SA is moving quickly to integrate the two companies. Sanofi has unveiled a research and development structure that will coordinate existing Genzyme and Sanofi research operations in Massachusetts through a new innovation unit called the Sanofi Boston R&D Hub. Genzyme’s own drug discovery programs, centered in Framingham, will operate within that unit as the Genzyme R&D Center.
